New Delhi, India

Vijay Kaul

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Ranbaxy Laboratories, Inc.. Active years: 2002-2011.

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 2.7

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2002-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Vijay Kaul - Innovator in Pharmaceutical Processes

Introduction

Vijay Kaul is a notable inventor based in New Delhi, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of processes for the manufacture of complex compounds. With a total of 2 patents to his name, his work has had a meaningful impact on the industry.

Latest Patents

Vijay Kaul's latest patents include a process for the manufacture of (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt. This invention relates to innovative methods for producing this specific compound. Additionally, he has developed a process for the preparation of isotretinoin, which is the 13-cis isomer of Vitamin A acid, commonly known for its use in treating severe acne.

Career Highlights

Vijay Kaul is currently associated with Ranbaxy Laboratories, Inc., where he continues to advance pharmaceutical research and development. His expertise in chemical processes has positioned him as a valuable asset in the company.

Collaborations

Throughout his career, Vijay has collaborated with notable colleagues, including Mohammad Salman and J Suresh Babu. These partnerships have fostered innovation and contributed to the successful development of his patented processes.

Conclusion

Vijay Kaul's contributions to pharmaceutical innovations through his patents and collaborations highlight his role as a key inventor in the industry. His work continues to influence the field and improve therapeutic options for patients.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…